Business Context and Reporting Period
MIMEDX GROUP, INC. filed this Form 8-K on October 19, 2009, to report the entry into a Material Definitive Agreement and the completion of an asset disposition. The registrant's wholly-owned subsidiary, MiMedx, Inc., sold its upper extremities business, known as Level Orthopedics, to UPex Holdings, LLC, a design and distribution company focused on upper extremity orthopedic products.
Key Financial Metrics and Transaction Details
The transaction closed on October 19, 2009, involving the sale of eight patent applications and related intellectual property. The total purchase price is up to $1,030,000, structured as follows:
- Cash at Closing: $300,000
- Secured Promissory Note: $100,000
- Royalty Obligations: Up to $630,000
The promissory note bears interest at 3% per annum and is payable in monthly installments of $5,000 plus accrued interest from January 1, 2010, through August 1, 2011. The note is secured by a security interest in the acquired intellectual property. Royalty payments are set at 5% of gross revenue generated by UPex from the intellectual property, capped at $630,000.
Material Changes
The primary material change is the divestiture of the Level Orthopedics business unit. Additionally, UPex assumed all duties and responsibilities under the existing Consulting Agreement dated September 21, 2007, between MiMedx, Inc. and Thomas J. Graham, M.D. The filing states that, other than this transaction, there are no material relationships between the Company and UPex.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, management commentary on future strategy, or a discussion of general risks beyond the terms of the agreement. The contingent nature of the $630,000 royalty component depends on UPex's future sales performance. The filing does not provide clear values for the Company's overall revenue, profit, cash flow, or debt levels outside of this specific transaction.
Key Facts for Investor Verification
- Verify the receipt of the $300,000 cash payment at closing.
- Confirm the terms and security interest of the $100,000 promissory note.
- Monitor future royalty payments to ensure they align with the 5% gross revenue rate and the $630,000 cap.
- Assess the impact of losing the Level Orthopedics intellectual property on the Company's remaining product portfolio.
- Review the status of the assumed consulting agreement with Thomas J. Graham, M.D.